title: Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning.
abstract: It has been demonstrated that cholinesterases (ChEs) are an effective mode of pretreatment to prevent organophosphate (OP) toxicity in mice and rhesus monkeys. The efficacy of ChE as a bioscavenger of OP can be enhanced by combining enzyme pretreatment with oxime reactivation, since the scavenging capacity extends beyond a stoichiometric ratio of ChE to OP. Aging has proven to be a major barrier to achieving oxime reactivation of acetylcholinesterase (AChE) inhibited by the more potent OPs. To further increase the stoichiometry of OP to ChE required, we have sought AChE mutants that are more easily reactivated than wild-type enzyme. Substitution of glutamine for glutamate (E199) located at the amino-terminal to the active-site serine (S200) in Torpedo AChE generated an enzyme largely resistant to aging. Here we report the effect of the corresponding mutation on the rate of inhibition, reactivation by 1-(2-hydroxyiminomethyl-1-pyridinium)-1(4-carboxyaminopyridinium)- dimethyl ether hydrochloride (HI-6), and aging of mouse AChE inhibited by C(+)P(-)- and C(-)P(-)-epimers of soman. The E202 to Q mutation decreased the affinity of soman for AChE, slowed the reactivation of soman-inhibited AChE by HI-6, and decreased the aging of mutant AChE. These effects were more pronounced with C(-)P(-)-soman than with C(+)P(-)-soman. In vitro detoxification of soman and sarin by wild-type and E202Q AChE in the presence of 2 mM HI-6 showed that, E202Q AChE was 2-3 times more effective in detoxifying soman and sarin than wild-type AChE. These studies show that these recombinant DNA-derived AChEs are a great improvement over wild-type AChE as bioscavengers. They can be used to develop effective methods for the safe disposal of stored OP nerve agents and potential candidates for pre- or post-exposure treatment for OP toxicity.
authors.affiliation: Walter Reed Army Institute of Research, Washington, DC 20307, U.S.A.
authors.forename: A
authors.initials: A
authors.lastname: Saxena
authors.forename: D M
authors.initials: DM
authors.lastname: Maxwell
authors.forename: D M
authors.initials: DM
authors.lastname: Quinn
authors.forename: Z
authors.initials: Z
authors.lastname: Radić
authors.forename: P
authors.initials: P
authors.lastname: Taylor
authors.forename: B P
authors.initials: BP
authors.lastname: Doctor
mesh_terms: D000110:Acetylcholinesterase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000378:metabolism*; D004793:Enzyme Reactivators / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D008658:Inactivation, Metabolic; D051379:Mice; D009154:Mutation; D009943:Organophosphorus Compounds / Q000378:metabolism* / Q000633:toxicity; D010091:Oximes; D011726:Pyridinium Compounds / Q000494:pharmacology; D014101:Torpedo
chemical_list: D002800:Cholinesterase Inhibitors; D004793:Enzyme Reactivators; D009943:Organophosphorus Compounds; D010091:Oximes; D011726:Pyridinium Compounds; D000110:Acetylcholinesterase; C022870:asoxime chloride